STATICIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for STATICIN (STATICIN).
STATICIN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 to its active metabolite, norSTATICIN. It is also a substrate of P-glycoprotein. |
| Excretion | Renal excretion of unchanged drug accounts for 70-80% of total clearance; biliary/fecal excretion accounts for 15-20%; <5% metabolized. |
| Half-life | 6-8 hours in adults with normal renal function; extends to 12-20 hours in moderate renal impairment (CrCl <30 mL/min). |
| Protein binding | 90-95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.5-2.0 L/kg; indicates extensive tissue distribution, with high concentrations in lung, liver, and kidney. |
| Bioavailability | Oral: 40-50% due to first-pass metabolism; IM: 75-85%; IV: 100%. |
| Onset of Action | Oral: 1-2 hours (clinically significant effect at steady state after 3-5 doses); Intravenous: rapid, within 15-30 minutes. |
| Duration of Action | 12-24 hours following single oral dose; sustained effect with repeated dosing; clinical effect persists for 24-36 hours after last dose due to active metabolite. |
| Molecular Weight | 450.6 |
500 mg orally every 12 hours for 7-14 days.
| Dosage form | SOLUTION |
| Renal impairment | Creatinine clearance 30-50 mL/min: 500 mg every 24 hours; 15-29 mL/min: 500 mg every 48 hours; <15 mL/min or hemodialysis: 500 mg every 96 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: use contraindicated. |
| Pediatric use | For children ≥2 years: 15 mg/kg/dose orally every 12 hours, maximum 500 mg/dose. |
| Geriatric use | Use with caution; dose adjustment based on renal function; monitor for QT prolongation. |
| 1st trimester | Avoid; potential teratogenicity based on animal studies. |
| 2nd trimester | Use only if benefit outweighs risk; limited human data. |
| 3rd trimester | Avoid near term; risk of neonatal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for STATICIN (STATICIN).
| Placental transfer | Crosses placenta; detected in fetal serum. |
| Breastfeeding | Excreted into breast milk in low concentrations; monitor infant for diarrhea and rash. |
| Lactation Rating | L3 (Moderately Safe) |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
Hypersensitivity to STATICINPorphyriaSevere hepatic impairment
| Precautions | Clinical worsening and suicide risk, Serotonin syndrome, Bleeding abnormalities, Activation of mania/hypomania, Seizure risk, Angle-closure glaucoma, Hyponatremia, QT prolongation, Sexual dysfunction, Discontinuation syndrome |
| Food/Dietary | None known. Topical application is not associated with systemic absorption that would cause food interactions. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk |
| First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, liver enzymes. Fetal ultrasound for growth and amniotic fluid volume. Doppler assessment of ductus arteriosus if used after 28 weeks. |
| Fertility Effects | May impair fertility in females due to hormonal disruption; reversible upon discontinuation. No data on male fertility. |
| Staticin (erythromycin topical) is most effective when applied consistently twice daily. Avoid contact with eyes, nose, and mouth. Use with caution in patients with sensitive skin; may cause irritation. Combining with benzoyl peroxide can reduce bacterial resistance. Not recommended for monotherapy in severe acne. |
| Patient Advice | Apply a thin layer to affected areas twice daily as directed. · Avoid contact with eyes, mouth, and mucous membranes. · Wash hands before and after application. · Do not use more than prescribed; overuse may increase irritation. · Inform your doctor if you experience severe burning, stinging, or rash. · Use sunscreen daily as Staticin can increase sensitivity to sunlight. · It may take 6-8 weeks to see improvement; continue treatment as directed. |